A New Treatment Strategy that Reduces Growth/Differentiation Factor-15 in Type-2 Diabetes Mellitus: Major Autohemotherapy: A Pilot Study

• Published in: Alternative therapies in health and medicine Vol. 29; no. 7; pp. 30 - 33
• Main Authors: Yucel, Hasan E, Ilanbey, Bilal
• Format: Journal Article
• Language: English
• Published: United States InnoVision Health Media, Inc 01.10.2023
• Subjects: Alternative medicine; Body mass index; Cholesterol; Chronic illnesses; Diabetes; Glucose; Hemoglobin; High density lipoprotein; Hospitals; Hyperglycemia; Inflammation; Lipids; Lipoproteins; Oxidative stress; Patients; Turkey
• ISSN: 1078-6791

Growth/differentiation factor-15 (GDF-15) is a diagnostic and prognostic marker associated with inflammation, renal damage, and cardiovascular risk in type-2 diabetes mellitus. Researchers have proposed treatment targets that reduce GDF-15 levels. Our aim in this study is to investigate the effect of major autohemotherapy on GDF-15 levels and to evaluate it as a complementary therapy. The research team designed a laboratory study to examine the effect of major hemotherapy on GDF-15 levels in patients with type-2 diabetes mellitus and healthy volunteers. Blood was drawn from the participants in a closed system, infused with ozone gas, and reinfused into the patients. The study was carried out from 15 August-5 October at Kırşehir Training and Research Hospital Traditional and Complementary Medicine Center, Turkey. The study was conducted prospectively, and two groups were formed, consisting of those with type-2 diabetes mellitus (n = 21) and healthy volunteers (n = 14). All participants received 10 sessions of major autohemotherapy at a concentration of 25-35 micrograms/milliliter twice a week. Before and after the application, GDF-15, fasting glucose, glycosylated hemoglobin, and lipid panel levels were studied and compared. Age, GDF-15, fasting glucose, glycosylated hemoglobin, and triglyceride levels were found to be higher in the type-2 diabetes mellitus group compared to the healthy group, and high-density lipoprotein cholesterol levels were found to be lower. After major autohemotherapy, GDF-15 and low-density lipoprotein cholesterol decreased significantly in the type-2 diabetes mellitus group. No change was observed in the healthy group. As a new treatment strategy, major autohemotherapy reduces GDF-15 levels in type-2 diabetes mellitus and contributes to the therapeutic effects of ozone therapy.